Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 19, 2011

View Archived Issues

Naftopidil has effects on stromal and cancer cells

New Wnt signaling inhibitors JW-74 and JW-67 inhibit tumor growth in vivo

New adenylate cyclase type 1 inhibitor NB-001 shows promise to treat neuropathic/inflammatory pain

Boehringer Ingelheim divulges new cannabinoid CB2 receptor agonists

BioCryst reports on phase III peramivir trials in influenza

Phase III data show benefits of Exparel after bunionectomy

PHD finger protein 6 is a tumor suppressor protein in AML

Vitae Pharma describes new 11-beta-HSD1 inhibitors

Adolor launches second phase II trial of ADL-5945 for opioid-induced constipation

New beta-secretase 1 inhibitors discovered at AstraZeneca

Cephalon patents new histamine H3 receptor antagonists/inverse agonists

Sirona Biochem reports on its sodium/glucose cotransporter 2 inhibitor for type 2 diabetes

Neovacs begins phase II TNF-K-005 trial of TNF-kinoid in Crohn's disease

Secondary endpoint met in phase III Corlux trial in Cushing's syndrome

Nabriva completes recruitment in phase II trial of BC-3781

Chugai grants Circadian Technologies global license to VEGF-D program

Abbott withdraws European MAA for Ozespa

Eli Lilly's Byetta is approved in Canada for type 2 diabetes

TransPharma Medical's ViaDerm becomes ViaDor

Phase III SUCCEED trial of oral ridaforolimus achieves primary endpoint

RG-7204 improves survival in phase III BRIM3 trial

Protalix provides update on programs in Gaucher's disease and Fabry's disease

Merck & Co. claims new inhibitors of Egl nine homolog 1, 2 and 3

New inhibitors discovered of polyamine transport into cancer cells

Astex Therapeutics begins first-in-human study of anticancer drug LEE-011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...